anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a new process for preparing a cinnamon, Radix aconiti lateralis preparata and rehmannia root preparation. The preparation comprises 1-2 parts of cinnamon, 1-2 parts of prepared Radix aconiti lateralis preparata, 8-16 parts of prepared rehmannia root, 4-8 parts of wine-prepared Fructus Corni, 3-6 parts of Cortex Moutan, 4-8 parts of Chinese yam, 3-6 parts of Poria cocos and 3-6 parts of Rhizoma Alismatis. The process has the following advantages: the above medicines are extracted by different solvents respectively according to the main effective components and their physical and chemical properties of the medicines, and a D101 macroporous adsorption resin column is adopted to separate, purify and remove impurities, so the taking amount of the preparation, which is greatly reduced, is 40-85% lower than the taking amount of original cinnamon, Radix aconiti lateralis preparata and rehmannia root preparations, and 87-96% lower than the taking amount of cinnamon, Radix aconiti lateralis preparata and rehmannia root pills. The preparation which adopts a fat-soluble matrix to disperse has the advantages of substantially shortened disintegration dispersion time limit, absorption benefiting after the dispersion of extracts in the matrix, biological utilization degree improvement, and treatment effect improvement. The process overcomes the discomfort of floating in the stomach after the taking of the original cinnamon, Radix aconiti lateralis preparata and rehmannia root preparations, and solves many abuses of the cinnamon, Radix aconiti lateralis preparata and rehmannia root pills prepared through using crude medicines. Animal experiments show that the preparation has a substantial improvement effect on the deficiency of kidney yang, acute toxicity tests show that the cinnamon, Radix aconiti lateralis preparata and rehmannia root preparation is safe in the clinical use, and the quality control substandard of the preparation is greatly improved than that of the Radix aconiti lateralis preparata and rehmannia root pills and original Radix aconiti lateralis preparata and rehmannia root capsules, so the quality stability and the treatment stability of finished products are guaranteed.
Areno complexes of ru (II) with oxime ligands with anticancer activity. The present invention relates to arene complexes of ru (II) with oxime ligands with anticancer activity, of formula (1) or (2), and which can be used in the treatment and/or prevention of cancer. For (1) and (2), r1 to r6 can be halide, h, alkyl or aryl, functionalized or not. R1 and r2 may also be part of a saturated or unsaturated, carbon or heterocyclic ring of 3 to 8 members. P is a counter-anion. N can be 0, 1 or 2. Z can be oh or o-. R1c and r2c can be h, alkyls, alkenyls or branched or linear alkynyls, cyclic, heterocyclic or acyclic, each of these may or may not be differently substituted. They can also be part of cyclic or heterocyclic, saturated, unsaturated or aromatic hydrocarbons, from 3 to 8 members. And it can be an amino or amido group, l is the linking group between x and y. (Machine-translation by Google Translate, not legally binding)
Participants weighing \<50 kg will receive 0.04 mg/kg of prucalopride oral solution (will draw the required volume from one bottle of 0.4 mg/mL and one bottle of placebo oral solution to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive one 2 mg of prucalopride oral tablet and one placebo oral tablet, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
FARXIGA was evaluated in 4304 adult patients with chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m2) in the DAPA-CKD trial. FARXIGA was also evaluated in 1926 adult patients with an eGFR of 30 to 60 mL/min/1.73 m2 in the DAPA-HF trial. The safety profile of FARXIGA across eGFR subgroups in these studies was consistent with the known safety profile [see Adverse Reactions (6.1) and Clinical Studies (14.4, 14.5)].

FARXIGA was evaluated in two glycemic control adult trials that included patients with type 2 diabetes mellitus with moderate renal impairment (an eGFR of 45 to less than 60 mL/min/1.73 m2[see Clinical Studies (14.1)], and an eGFR of 30 to less than 60 mL/min/1.73 m2, respectively). Patients with diabetes and renal impairment using FARXIGA may be more likely to experience hypotension and may be at higher risk for acute kidney injury secondary to volume depletion. In the trial of adult patients with an eGFR 30 to less than 60 mL/min/1.73 m2, 13 patients receiving FARXIGA experienced bone fractures compared to none receiving placebo. Use of FARXIGA for glycemic control in patients without established CV disease or CV risk factors is not recommended when eGFR is less than 45 mL/min/1.73 m2[see Dosage and Administration (2.1)].

Efficacy and safety trials with FARXIGA did not enroll patients with an eGFR less than 25 mL/min/1.73 m2 or on dialysis. Once enrolled in the DAPA-CKD and DELIVER trials, adult patients were not required to discontinue therapy if eGFR fell below 25 mL/min/1.73 m2 or if dialysis was initiated. Once enrolled in the DAPA-HF trial, adult patients were not required to discontinue therapy if eGFR fell below 30 mL/min/1.73 m2 or if dialysis was initiated [see Dosage and Administration (2.3) and Clinical Studies (14.4,14.5)].
Accumulating studies suggest that splicing factors play important roles in many diseases including human cancers. Our study revealed that WBP11, a core splicing factor, is highly expressed in ovarian cancer (OC) tissues and associated with a poor prognosis. WBP11 inhibition significantly impaired the proliferation and mobility of ovarian cancer cells in vitro and in vivo. Furthermore, FOXM1 transcriptionally activated WBP11 expression by directly binding to its promoter in OC cells. Importantly, RNA-seq and alternative splicing event analysis revealed that WBP11 silencing decreased the expression of MCM7 by regulating intron 4 retention. MCM7 inhibition attenuated the increase in malignant behaviors of WBP11-overexpressing OC cells. Overall, WBP11 was identified as an oncogenic splicing factor that contributes to malignant progression by repressing intron 4 retention of MCM7 in OC cells. Thus, WBP11 is an oncogenic splicing factor with potential therapeutic and prognostic implications in OC.
Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
Patients will stay in the hospital for 4-5 hours per visit (for screening about 30 min) for physical examination, blood draw, MRI scans, radiographs of knees and hands (only at baseline and 24 months), CT scan of the knee (only at baseline and 24 months), low radiation whole body CT scan (only at baseline and 24 months), HandScan (only at baseline and 24 months), motion analysis, and performance based tests. They will be asked to fill out questionnaires about knee, hand and hip osteoarthritis, and about general health and pain. The patient council in the consortium indicated that the load is acceptable. The patient council will be involved in the execution of the study. The assumed risk is minimal for an individual patient and minimal compared to the contribution to the development of knowledge of their disease. These risks include minimal events due to blood sampling itself (such as hematoma or localized bleeding), radiation exposure by radiographic imaging techniques (with a minimal increased healthcare risk), and exposure to MRI techniques (without known risks and without use of contrast agents).
"Anti-pseudomonas IgY" is prepared from eggs of hens that have been vaccinated with Pseudomonas aeruginosa. The hens farm is under veterinary control according to Swedish rules. The drug is prepared with a water dilution method according to GMP standards (approved by Swedish MPA). Patients with CF who are intermittently but not chronically infected with P. aeruginosa get a short course of antibiotics to eradicate the bacteria. Thereafter they start to gargle with a solution of "anti-pseudomonas IgY" every night to prevent a new infection. Preliminary results have shown that it takes a significantly longer time to get a new infection and that the patients get fewer infections than control patients. In addition, results tentatively indicate that: patients have not got any new opportunistic bacteria or fungi (B. Cepacia, S. Maltophilia, A. Xylosoxidans, atypical Mycobacteria, Aspergillus Fumigatus); that use of antibiotics is greatly diminished; that the lung functions and nutritional conditions are maintained.
The investigators will include 167 patients under surveillance for AAA who are all currently under the threshold for repair (i.e. AAA diameter 40-50 mm for men and 35-45 mm for women). Participants will be recruited from all collaborating hospitals (Radboudumc, Rijnstate, CWZ) after providing written informed consent. Additionally, AAA-patients under surveillance of general practitioners are eligible (and will be contacted through the hospital-links), since the nature of the tests allow for performing all tests at the general practitioners' office.

In this observational, prospective study, a total of 167 patients under surveillance for an AAA, who are currently under threshold for repair (i.e. AAA diameter 40-50 mm for men and 35-44 mm for women), will be included. Baseline patient characteristics will be registered, including traditional risk factors and CV-history. In addition to regular care of measuring AAA diameter progression (in mm/year), the investigators will perform the CAR-test (10-min) and non-invasive arterial stiffness measures (PWA and PWV with the SphygmoCor device (10-min) one time as baseline. Furthermore, the investigators will ask patients to complete a questionnaire about the quality of their life (Appendix 1). A second questionnaire tries to clarify the disease experience of the patients and can be found in Appendix 2. Both questionnaires will be asked to be completed at the start and the end of the study. Subsequently, the investigators will record major adverse cardiovascular events (MACE) according to the International Classification of Disease-10. Registration of MACE will be performed using hospital-records and following international guidelines. Across a 2-year follow-up, by means of regular follow-up appointments, the investigators will examine AAA progression (in mm/year) and the ability of the CAR parameter and arterial stiffness parameters to predict CV-events.
Catheter-related infections (CRI) are a serious healthcare problem due to their potential to cause serious complications, including bacteraemia or infective endocarditis, and to increase patient morbidity and mortality. In addition, these in fections significantly prolong hospital stay and cost. Preventing CRI is crucial and is considered a criterion for quality and safety in healthcare. For these reasons, the Spanish Society of Cardiovascular Infections (SEICAV) has considered it pertinent to review this topic, with experts in different areas including clinical microbiologists, infectious disease specialists, surgeons and nurses. The data were presented at a session held at the Ramón Areces Foundation, which was organised in the form of specific questions grouped into three round tables. The first panel analysed the scale of the problem including epidemiological, clinical and diagnostic aspects; the second panel addressed advances in the treatment of CRI; and the third panel reviewed developments in the prevention of CRI. The recorded session is available on the Areces Foundation website and we believe it maybe of interest not only to health professionals, but also to any non-expert citizen interested in the subject.
The invention discloses a Chinese herbal medicine used for treating female dampness obesity infertility. The Chinese herbal medicine is prepared from medicines of, by weight: 6 to 18 parts of ginseng, 6 to 18 parts of mongolian milkvetch root, 6 to 18 parts of ligusticum, 3 to 6 parts of Chinese thorowax root, 24 to 30 parts of largehead atractylodes rhizome, 34 to 36 parts of tuckahoe, 24 to 36 parts of tuber fleeceflower root, 1 to 5 parts of tangerine peel, 6 to 12 parts of snoothfruit ventilago root, 12 to 24 parts of suberect spatholobus stem, 18 to 24 parts of glossy privet fruit, and 6 to 18 parts of swordlike atractylodes rhizome. The medicines are decocted into a traditional Chinese medicine decoction; the decoction is filtered, bottled, sterilized, and preserved for later use. According to the invention, ginseng is adopted as a monarch drug; mongolian milkvetch root and ligusticum are adopted as minister drugs; Chinese thorowax root, largehead atractylodes rhizome, tuckahoe, and tuber fleeceflower root are adopted as assistant drugs; and tangerine peel, snoothfruit ventilago root, uberect spatholobus stem, glossy privet fruit, and swordlike atractylodes rhizome are adopted as guide drugs. The Chinese herbal medicine preparation provided by the invention is advantaged in simple operation, abundant medicine resource, low production cost, and easy administration. The Chinese herbal medicine preparation is safe, and causes no side-effect. The medicine provides main functions of water retention alleviating and phlegm dissipating, and auxiliary functions of vital energy and blood nourishing, and dampness removing. The medicine is a Chinese herbal medicine oral aqua used for treating female dampness obesity infertility.
<P>PROBLEM TO BE SOLVED: To provide safe and highly effective agents for increasing adiponectin in blood.  <P>SOLUTION: New, safe and highly effective agents for increasing adiponectin in blood, which contain astaxanthin and/or an ester thereof as an active component, are provided. Due to an increase in the amount of adiponectin in blood, the adverse action of adipocytokine such as TNFα can be decreased, or the action of biologically active substances such as insulin can be protected from the adverse action of adipocytokine. It is expected that, as a result, insulin resistance and hyperinsulinemia caused by adipocytokine, and metabolic syndromes are prevented or suppressed. Furthermore, it is expected that progress of arteriosclerosis, which can lead to cardiovascular diseases and cerebrovascular diseases, is inhibited by ingestion of the agent for increasing adiponectin in blood, because arteriosclerosis progresses due to decrease in adiponectin.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from Aβ(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice. The MnMs were demonstrated to protect the mitochondrial population in neurons in an in vivo model of Alzheimer's Disease. Also described is a method for treating a patient suffering from a disorder characterized by dysfunction of neuronal mitostasis, comprising administering to the patient a therapeutically effective amount of a compound (MnM), or a pharmaceutically acceptable salt thereof.
Peginterferon is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
Iron metabolism disorder has been identified as a contributor to the pathogenesis and progression of multiple cognitive dysfunction-related diseases, including postoperative delirium. However, the association between preoperative iron reserves and postoperative delirium risk remains elusive. This retrospective cohort study aimed to explore the impact of preoperative serum ferritin levels on the risk of postoperative delirium in elderly patients undergoing non-neurosurgical and non-cardiac procedures. Conducted at the Chinese PLA General Hospital between January 2014 and December 2021, the study finally included 12,841 patients aged 65 years and above. Preoperative serum ferritin levels were assessed within 30 days before surgery, and postoperative delirium occurrence within the first seven days after surgery was determined through medical chart review. The analyses revealed that both low and high levels of serum ferritin were associated with an increased risk of postoperative delirium. Patients in the lowest quintile of serum ferritin exhibited an 81% increased risk, while those in the highest quintile faced a 91% increased risk compared to those in the second quintile. Furthermore, mediation analyses indicated that the direct effect of preoperative serum ferritin on postoperative delirium contradicted its indirect effect mediated by hemoglobin levels. These findings suggest that maintaining serum ferritin within moderate range preoperatively could be beneficial for managing postoperative delirium risk among elderly patients.
BACKGROUND: Borderline personality disorder (BPD) is a serious disorder with a lifetime prevalence of 2.7-5.9% and is thought to correlate with altered neuroplasticity. The aim of the present study is to investigate possible associations of BPD (-severity) and alterations in neurological soft signs (NSS) and olfactory function.
METHODS: For the monocentric observational study, 39 female subjects with a BPD diagnosis and 19 female healthy control subjects were recruited. The groups were matched by age. Olfactory functions were examined using Sniffin' Sticks. NSS were assessed by a standardized test with 50 items.
RESULTS: BPD subjects have higher NSS scores in group comparison. By contrast, there are no alterations in the total score of olfactory function, while the BPD subjects scored higher in smell identification. Within the BPD group, the total NSS score was discovered to have a negative correlation with olfactory function. BPD subjects taking antipsychotics show more NSS than those without. We found no significant influence of posttraumatic stress disorder on the NSS or olfactory function. The BPD-severity correlates with NSS.
LIMITATIONS: Due to the cross-sectional design, we did not have a follow up examination. The sample size was small, and all patients had psychiatric comorbidities. Additionally, we did not perform MRI to connect our findings with possible structural abnormalities.
CONCLUSIONS: Our study confirmed altered NSS in BPD patients, whereas no impairment in the olfactory function was found. Further research is required to establish NSS and smell tests as clinical screening tools in BPD patients and to uncover the disorder's impact on neuroplasticity.
This study aims to characterize the pharmacokinetic profile of colchicine and its three main metabolites, after a regimen of 1.8 mg over two hours. After a fast of at least 10 hours, fifteen healthy non-smoking, non-obese, non-pregnant adult volunteers between the ages of 18 and 55 will be given colchicine 1.2 mg (2 x 0.6 mg) orally followed by an additional single 0.6mg dose one hour later. Fasting will continue for 4 hours after the first dose at which time a standardized meal will be served. Blood will be drawn from all participants at times sufficient to adequately define the pharmacokinetics of colchicine and its 3 major metabolites, 2, 3 and 10 demethylcolchicine. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. To this end, subjects will be monitored throughout participation in the study for adverse reactions to the study drug and/or procedures. Seated and standing blood pressure and pulse will be measured prior to the first dose and 0.5, 1, 2, 4, and 12 hours post-dose. Twelve-lead electrocardiograms will be obtained at the same time points. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the Investigator and reported in the subject's case report form.
An oral treatment composition for local application is provided. The composition includes a combination of potassium nitrate and hexylene glycol. The composition also includes a fluoride compound, preferably sodium fluoride. 100ml of the composition will include about 7.Og potassium nitrate, about 30ml hexylene glycol and about 0.25g of sodium fluoride. The composition is conveniently provided as an aqueous mouthwash solution and is suited for use in the treatment of mucositis and other oral ailments in patients that have a compromised immune system or that have undergone radiotherapy and/or chemotherapy. The composition may also be a cream or paste suitable for oral application.
Systems and methods for designing and delivering a nutritional supplement regime are provided. The nutritional supplement regime may include, for example, various nutritional supplements which are commonly available over-the-counter. Each nutritional supplement may be directed towards a specific problem, deficiency, or activity of the individual. The individual may provide information in connection with his or her specific problems, deficiencies, or activities by, for example, completing a questionnaire. The individual may access the questionnaire using a communications network such as, for example, the Internet. The nutritional supplements may be assembled into a kit which may be delivered to the individual at an appropriate time.
Participants in Cohort 4 (HER2-positive) will be treated with nal-IRI (50 mg/m\^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m\^2 over 46 hrs), oxaliplatin (60 mg/m\^2), and pembrolizumab (400 mg). Each cycle is 42 days. Participants will receive chemotherapy and trastuzumab treatments on day 1, 15, and 29 of each cycle. Pembrolizumab will be given on day 1 of each cycle.
Two training sessions per week will be completed for three consecutive weeks. Each training session will last 0.5-1 hour with an active training time of 30 minutes per participant. Training will involve repeated volitional and reactive stepping movements that mimic the movements necessary to recover balance after tripping while walking.
Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
A method and system for evaluating a machine learning model that provides predictions about a patient's disease state from 2D or 3D images of the patient or samples obtained therefrom. The machine learning model generates predictions of disease states from the images. The method involves presenting an image of the patient or a sample obtained therefrom, and a risk score or classification associated with the prediction on a display of the workstation. The image is further enhanced with highlights to indicate one or more regions in the image that affect the prediction produced by the machine learning model. A tool is provided by which a user can highlight one or more regions in the image that the user deems suspicious to the disease state. Inference is performed by the machine learning model on the user-highlighted regions. The results of the inference are presented to the user via a display.